Smoldering Multiple Myeloma

SAN DIEGO — Daratumumab monotherapy significantly delayed progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring, according to results of the randomized phase 3 AQUILA study.

Irene Ghobrial, MD, will receive the William Dameshek Prize at this year’s ASH Annual Meeting & Exposition.